In addition, it has been shown that a group of ETV6::RUNX1-rearranged B-cell precursor ALL (BCP-ALL) patients may benefit from reductions in the intensity of chemotherapy. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.